INS and type 1 diabetes mellitus: Isorhamnetin (ISO) alleviates hyperglycemia in STZ-induced T1DM, lowers LDL-C, increases plasma insulin (L-ISO), and preserves islet morphology (significant in L-ISO; Figure 1).